drugset
drugset / Trial / NCT05824858

A Study of the Effect of Food on LY3537982 in Healthy Participants

NCT05824858 ↗

Phase 1 Completed 48 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 after meals and on an empty stomach. The study will also evaluate the safety and tolerability of LY3537982. Participants will stay in the research center during the study, which will last about one week, not including screening.

Timeline

Start
2023-04-12
Primary completion
2023-06-17
Completion
2023-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Olomorasib Small molecule — Oral

Indications

No indication recorded.